# ZEN-3694

Source: https://onco.cc/drugs/zen-3694/  
OnCo record `zen-3694` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZEN-3694 is a BET inhibitor from Zenith Epigenetics being tested in NUT carcinoma, where the cancer's driving fusion is itself a BET protein, and in prostate and breast cancers.

## Summary

BET inhibitors block the bromodomain proteins that switch on growth genes such as MYC. NUT carcinoma is the clearest use: its BRD4-NUT fusion is a BET protein, and inhibitors make the cells differentiate in the laboratory, with objective but short-lived responses in early trials of molibresib and birabresib. ZEN-3694 is the BET inhibitor now carrying that idea forward in National Cancer Institute trials with platinum chemotherapy and with abemaciclib in NUT carcinoma, and it has been studied with enzalutamide in castration-resistant prostate cancer and with talazoparib in triple-negative breast cancer. Thrombocytopenia and fatigue are the class side effects.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-08
- Also known as: ZEN003694; Zenith BET inhibitor
- Tags: gap-fill; owner-request
- Modality: Oral small-molecule BET bromodomain inhibitor
- Mechanism: Binds the bromodomains of BRD2, BRD3 and BRD4 so they cannot read acetylated histones; in NUT carcinoma this displaces the BRD4-NUT fusion from chromatin and lets the cells differentiate, and in other cancers it lowers MYC and androgen receptor signalling.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/BET_inhibitor
- NCI trial with platinum chemotherapy, NCT05019716: https://clinicaltrials.gov/study/NCT05019716
- NCI trial with abemaciclib, NCT05372640: https://clinicaltrials.gov/study/NCT05372640

## Connected records

- cancers: [NUT carcinoma (midline carcinoma with NUTM1 rearrangement)](https://onco.cc/cancers/nut-carcinoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- trials: [ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)](https://onco.cc/trials/zen-3694-abemaciclib-nut/), [ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)](https://onco.cc/trials/zen-3694-platinum-nut/), [ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct04986423/)

---
JSON: https://onco.cc/api/v1/entities/zen-3694.json